Integer reports Q2 sales of $464 million, withdraws outlook amid $5.7 billion KKR deal

Integer Holdings Corporation reported second-quarter 2026 sales of $464 million, down 2.6% from a year earlier, while withdrawing its financial outlook and canceling its August 6 earnings call after agreeing to be acquired by KKR in an all-cash transaction valued at a $5.7 billion enterprise value. Under the merger agreement, Integer stockholders are set to receive $127 per share in cash. The medical device CDMO posted weaker GAAP profitability for the quarter, with operating income from continuing operations down 42% to $35 million and income from continuing operations down 36% to $24 million, while adjusted results were more resilient, including adjusted EPS of $1.60, up 3%. Product-line performance was mixed, with Cardio & Vascular sales slipping to $280 million, Cardiac Rhythm Management & Neuromodulation edging up to $174 million, and Other Markets declining to $10 million, primarily due to the Portable Medical exit. Total debt rose to $1.238 billion at July 3, 2026, with leverage at 3.2 times adjusted EBITDA. Separately, Monteverde & Associates PC said it is investigating Integer's sale to KKR and whether the proposed $127-a-share cash consideration is fair to shareholders.